A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), in Patients With Hyperkalemia-HARMONIZE Asia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Acronyms HARMONIZE Asia
- Sponsors AstraZeneca
- 18 Dec 2018 Planned End Date changed from 7 Oct 2019 to 9 Mar 2020.
- 18 Dec 2018 Planned primary completion date changed from 7 Oct 2019 to 9 Mar 2020.
- 18 Dec 2018 Planned initiation date changed from 14 Dec 2018 to 8 May 2019.